Lung Disease Associated With Rheumatoid Arthritis
|ClinicalTrials.gov Identifier: NCT00001876|
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : March 1, 2018
Pulmonary fibrosis (PF) is a condition in which the lungs of a patient become scarred and fibrous. It has been known to occur in as many as 40% of patients diagnosed with rheumatoid arthritis (RA). The cause of the pulmonary fibrosis in patients with RA is unknown.
Patients participating in this study will undergo a series of tests and examinations before and throughout the study. The tests include blood and urine tests, electrical measures of heart function (ECG), chest x-rays, CAT scans, nuclear medicine scans, breathing tests, exercise tests, and fiberoptic bronchoscopy.
The goals of this study are to:
- Estimate how common pulmonary fibrosis is in patients with rheumatoid arthritis,
- Describe the natural course of pulmonary fibrosis in patients with rheumatoid arthritis,
- Estimate the survival rate of patients with pulmonary fibrosis and rheumatoid arthritis, and
- Learn more about the factors that contribute to the development or progression fibrotic lung disease.
|Condition or disease|
|Pulmonary Fibrosis Rheumatoid Arthritis|
|Study Type :||Observational|
|Actual Enrollment :||132 participants|
|Official Title:||Pulmonary Fibrosis Associated With Rheumatoid Arthritis: Definition of the Natural History of Disease|
|Study Start Date :||March 1, 1999|
U.S. FDA Resources
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001876
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Bernadette R Gochuico, M.D.||National Human Genome Research Institute (NHGRI)|